trending Market Intelligence /marketintelligence/en/news-insights/trending/7yqJREUTENxnS2jBvPLkQQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Verrica to seek approval for skin treatment after positive results in 2 trials

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Verrica to seek approval for skin treatment after positive results in 2 trials

Verrica Pharmaceuticals Inc. said it will seek U.S. approval for its skin treatment VP-102 during the second half of the year after it cleared two late-stage studies.

The Camp-1 and Camp-2 clinical trials evaluated the efficacy and safety of VP-102 against placebo in 528 patients with molluscum contagiosum — a common skin disease that occurs mainly in children. The U.S. Food and Drug Administration has yet to approve a treatment for the disease, which is caused by a poxvirus and affects about 6 million people in the U.S. each year.

VP-102 achieved complete clearance of all treatable lesions in 46% and 54% patients after 84 days of treatment in the Camp-1 and Camp-2 phase 3 studies, respectively. This compares to the 18% and 13% of patients in the placebo groups.

The West Chester, Pa.-based drugmaker said the medicine did not cause any major side effects.